Three experts discuss recent developments in the diagnosis & treatment of APS & the future direction of research.
COVID-19 Risks & Treatment for Patients with Rheumatic Disease
The Global Rheumatology Alliance is an important tool for assessing COVID-19 risk, & the ACR COVID-19 Task Force provides treatment guidance to rheumatology practitioners.
Check It Out: Understanding Immune-Related Adverse Events from Immune Checkpoint Inhibitors
Immune checkpoint inhibitors effectively treat malignancy in ways that were not possible just a few years ago, but immune-related adverse events are a potential side effect.
L. Manuela Marinescu, MD, Takes Reins as Chair of Affiliate Society Council
While an active member of her state rheumatology society, L. Manuela Marinescu, MD, saw the value of connecting with other regional groups to share information and advocacy strategies. On Nov. 16, she assumed the role of chair of the ACR’s Affiliate Society Council (ASC), where she will help facilitate those connections. Dr. Marinescu graduated with…
Effects of Warfarin on Risk of Hip & Knee Replacement in OA Patients
The use of warfarin may increase the risk of knee or hip replacement in patients with osteoarthritis (OA), according to research presented during ACR Convergence 2020.
Emergency Use Approved for Baricitinib with Remdesivir Combination Therapy for SARS-CoV-2
The FDA issued an emergency use authorization for the use of baricitinib combined with remdesivir to treat patients hospitalized with COVID-19.
Riding Out the Pandemic: A Q&A with Norman Gaylis, MD
Some aspects of community practice are normalizing amid the ongoing COVID-19 pandemic, but the financial fallout and the need for increased safety precautions remain challenging.
Resetting Immune Tolerance to Prevent RA
Three experts discuss the current evidence on potential pathogenic mechanisms underlying preclinical RA autoimmunity and subsequent active disease.
What Does the ‘New Normal’ Look Like? A Q&A with Jay Mehta, MD
With his clinic resuming in-person visits, Jay Mehta, MD, says his patients and staff have proved remarkably adaptable, embracing telemedicine during the early days of the pandemic and now facemasks during appointments.
Pulmonary Adverse Events with Low-Dose Methotrexate
In this large placebo-controlled trial, Sparks et al. examined the predictors and severity of pulmonary adverse events (AEs) in patients taking low-dose MTX. The researchers found that low-dose MTX increased the risk of pulmonary AEs, including possible pneumonitis.
- « Previous Page
- 1
- …
- 164
- 165
- 166
- 167
- 168
- …
- 811
- Next Page »